Study of Multiple Ascending Dose of KBL693 in Healthy Participants

Moderate to Severe Asthma Clinical Trial

Official title:
A Phase I Randomised Double-Blind Placebo-Controlled Study of Multiple Ascending Dose of KBL693 in Healthy Participants

Status Completed

Clinical Trial Summary

The study is designed to investigate the safety and tolerability of KBL693 in healthy volunteers. KBL693 has been developed as a potential new treatment for moderate to severe asthma..

Clinical Trial Description

This is a randomized, double-blind, placebo-controlled, single centre Phase I study. Eighteen (18) subjects are planned to be randomised at 1 site across the 2 parts of the study as follows: - Cohort 1: 680 mg/day - Cohort 2: 6800 mg/day ;

Study Design

Related Conditions & MeSH terms

Moderate to Severe Asthma

Clinical Trial Details

NCT number	NCT04307173
Study type	Interventional
Source	KoBioLabs
Contact
Status	Completed
Phase	Phase 1
Start date	August 14, 2020
Completion date	November 12, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03556683` - Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics	N/A
Recruiting	`NCT05774340` - A Study of CM326 in Subjects With Moderate to Severe Asthma	Phase 2
Recruiting	`NCT05851443` - A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma	Phase 2
Recruiting	`NCT06385236` - Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping	Phase 4
Completed	`NCT05062759` - Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma	Phase 3
Recruiting	`NCT05761028` - A Study of CM310 in Subjects With Moderate to Severe Asthma	Phase 2/Phase 3